USPTO Grants Patent for Flavivirus Cross Neutralizing Antibody
Summary
The USPTO has granted patent US12583912B2 for a flavivirus cross-neutralizing antibody developed by the Japan Institute for Health Security. This antibody specifically targets the E protein of flaviviruses, including Zika, dengue, and Japanese encephalitis viruses, and aims to control infection with suppressed Antibody-Dependent Enhancement (ADE).
What changed
The United States Patent and Trademark Office (USPTO) has granted patent US12583912B2 to the Japan Institute for Health Security for a novel flavivirus cross-neutralizing antibody. This antibody is designed to bind to specific domains of the E protein in flaviviruses, including Zika virus, dengue virus types 1-4, and Japanese encephalitis virus, with the aim of controlling infection while mitigating Antibody-Dependent Enhancement (ADE).
This patent grant signifies the recognition of a new therapeutic development in the field of infectious diseases. While patent grants themselves do not impose direct compliance obligations on regulated entities, they are crucial for companies involved in the research, development, and manufacturing of pharmaceuticals, particularly those targeting viral infections. Companies in this sector should be aware of this patent as it may impact their intellectual property landscape and potential market exclusivity for related products.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Flavivirus cross neutralizing antibody and pharmaceutical composition
Grant US12583912B2 Kind: B2 Mar 24, 2026
Assignee
JAPAN INSTITUTE FOR HEALTH SECURITY
Inventors
Yoshimasa Takahashi, Arnone Nithichanon, Takayuki Matsumura, Ryosuke Suzuki, Chang-Kweng Lim, Ganjana Lertmemongkolchai
Abstract
Provided is a flavivirus cross neutralizing antibody which has an excellent ability to control infection with suppressed ADE. This is a flavivirus cross neutralizing antibody that specifically binds to domains of E protein of flavivirus and thereby has an ability to control infection with at least two viruses included in the flavivirus. The domains of E protein include a plurality of domains including domain III. The flavivirus includes, for example, Zika virus, dengue virus types 1-4, and Japanese encephalitis virus.
CPC Classifications
A61P 31/14
Filing Date
2021-02-04
Application No.
17801075
Claims
6
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.